Homozygous focal deletions of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene have been observed in highly proliferative meningiomas, such as anaplastic WHO grade 3 meningiomas [58,59,60]. This evidence concerns the gene CDKN2A and meningioma.